| The cancer preventative agent resveratrol is converted to the anticancer agent piceatannol by the cytochrome P450 enzyme CYP1B1 GA Potter, LH Patterson, E Wanogho, PJ Perry, PC Butler, T Ijaz, ... British journal of cancer 86 (5), 774-778, 2002 | 510 | 2002 |
| Characteristics of a novel deep red/infrared fluorescent cell‐permeant DNA probe, DRAQ5, in intact human cells analyzed by flow cytometry, confocal and multiphoton microscopy PJ Smith, N Blunt, M Wiltshire, T Hoy, P Teesdale‐Spittle, MR Craven, ... Cytometry: The Journal of the International Society for Analytical Cytology …, 2000 | 219 | 2000 |
| AQ4N: a new approach to hypoxia-activated cancer chemotherapy LH Patterson, SR McKeown British journal of cancer 83 (12), 1589-1593, 2000 | 209 | 2000 |
| Tumour cytochrome P450 and drug activation LH Patterson, GI Murray Current pharmaceutical design 8 (15), 1335-1347, 2002 | 194 | 2002 |
| Rationale for the use of aliphatic N-oxides of cytotoxic anthraquinones as prodrug DNA binding agents: a new class of bioreductive agent LH Patterson Cancer and Metastasis Reviews 12, 119-134, 1993 | 178 | 1993 |
| A novel cell permeant and far red-fluorescing DNA probe, DRAQ5, for blood cell discrimination by flow cytometry PJ Smith, M Wiltshire, S Davies, LH Patterson, T Hoy Journal of immunological methods 229 (1-2), 131-139, 1999 | 127 | 1999 |
| Examination of the distribution of the bioreductive drug AQ4N and its active metabolite AQ4 in solid tumours by imaging matrix‐assisted laser desorption/ionisation mass … SJ Atkinson, PM Loadman, C Sutton, LH Patterson, MR Clench Rapid Communications in Mass Spectrometry: An International Journal Devoted …, 2007 | 117 | 2007 |
| Antitumour prodrug development using cytochrome P450 (CYP) mediated activation. LH Patterson, SR McKeown, T Robson, R Gallagher, SM Raleigh, S Orr Anti-Cancer Drug Design 14 (6), 473-486, 1999 | 117 | 1999 |
| Enzymology of tirapazamine metabolism: a review AV Patterson, MP Saunders, EC Chinje, LH Patterson, IJ Stratford Anti-cancer drug design 13 (6), 541-573, 1998 | 117 | 1998 |
| Comparative computer graphics and solution studies of the DNA interaction of substituted anthraquinones based on doxorubicin and mitoxantrone SA Islam, S Neidle, BM Gandecha, M Partridge, LH Patterson, JR Brown Journal of medicinal chemistry 28 (7), 857-864, 1985 | 115 | 1985 |
| Polysialyltransferase: a new target in metastatic cancer R A Falconer, R J Errington, S D Shnyder, P J Smith, L H Patterson Current cancer drug targets 12 (8), 925-939, 2012 | 112 | 2012 |
| Enhancement of chemotherapy and radiotherapy of murine tumours by AQ4N, a bioreductively activated anti-tumour agent LH Patterson, SR McKeown, K Ruparelia, JA Double, MC Bibby, S Cole, ... British journal of cancer 82 (12), 1984-1990, 2000 | 112 | 2000 |
| AQ4N: an alkylaminoanthraquinone N-oxide showing bioreductive potential and positive interaction with radiation in vivo SR McKeown, MV Hejmadi, IA McIntyre, JJA McAleer, LH Patterson British journal of cancer 72 (1), 76-81, 1995 | 111 | 1995 |
| BIOREDUCTIVELY ACTIVATED ANTITUMOR N-OXIDES: THE CASE OF AQ4N, A UNIQUE APPROACH TO HYPOXIA-ACTIVATED CANCER CHEMOTHERAPY LH Patterson Drug metabolism reviews 34 (3), 581-592, 2002 | 110 | 2002 |
| Function and antagonism of β HM Sheldrake, LH Patterson Current cancer drug targets 9 (4), 519-540, 2009 | 103 | 2009 |
| Strategies to inhibit tumor associated integrin receptors: rationale for dual and multi-antagonists: miniperspective HM Sheldrake, LH Patterson Journal of medicinal chemistry 57 (15), 6301-6315, 2014 | 100 | 2014 |
| Involvement of human cytochromes P450 (CYP) in the reductive metabolism of AQ4N, a hypoxia activated anthraquinone di-N-oxide prodrug SM Raleigh, E Wanogho, MD Burke, SR McKeown, LH Patterson International Journal of Radiation Oncology* Biology* Physics 42 (4), 763-767, 1998 | 99 | 1998 |
| DNA topoisomerase II-dependent cytotoxicity of alkylaminoanthraquinones and their N-oxides PJ Smith, NJ Blunt, R Desnoyers, Y Giles, LH Patterson Cancer chemotherapy and pharmacology 39, 455-461, 1997 | 91 | 1997 |
| Development of a novel tumor-targeted vascular disrupting agent activated by membrane-type matrix metalloproteinases JM Atkinson, RA Falconer, DR Edwards, CJ Pennington, CS Siller, ... Cancer research 70 (17), 6902-6912, 2010 | 77 | 2010 |
| Tertiary amine N-oxides as bioreductive drugs: DACA N-oxide, nitracrine N-oxide and AQ4N. WR Wilson, WA Denny, SM Pullen, KM Thompson, AE Li, LH Patterson, ... The British journal of cancer. Supplement 27, S43, 1996 | 77 | 1996 |
